PARP inhibitorPhase 3 trialInvestigational
Talazoparib
How it works
Talazoparib is a medication that blocks the PARP enzyme, which is involved in DNA repair. By blocking PARP, talazoparib can kill cancer cells that have defects in DNA repair.
Cancer types
Pancreatic Cancer— BRCA-mutated
Ovarian Cancer— BRCA-mutated
Breast Cancer— BRCA1/2-mutated
Prostate Cancer— BRCA1/2-mutated
Colorectal Cancer— BRCA-mutated
Efficacy
In clinical trials, talazoparib improved progression-free survival in patients with pancreatic cancer and a BRCA1/2 mutation, with a median progression-free survival of approximately 3.9 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Tirapazamine and PARP Inhibitor Combination Shows Promise in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combining Talazoparib and Enzalutamide for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Talazoparib with or without Enzalutamide in Men with Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Understanding Cancer Cells' Resistance to Treatment | Breast Cancer | lab-study | — | Source → |
| Understanding Resistance to Cancer Treatment in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Testing Talazoparib and Radiation Therapy for Locally Recurrent Gynecologic Cancers | Ovarian Cancer | phase-1 | — | Source → |
| Study of Talazoparib and Enzalutamide in Men with Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Talazoparib Trial for Advanced Cancer | Breast Cancer | phase-2 | — | Source → |
| PARP Inhibitor Talazoparib Shows Promise in Treating Breast and Ovarian Cancers | Breast Cancer | review | Talazoparib has the highest potency (IC = 0.57 nM), which is 4-10 times lower than that of other PARP inhibitors. | Source → |
| New Formulation of Cancer Drug Talazoparib Gets Approval | Prostate Cancer | phase-3 | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| New Combination Therapy May Improve Prostate Cancer Outcomes | Prostate Cancer | phase-3 | Talazoparib plus enzalutamide was statistically superior to olaparib plus abiraterone acetate for radiographic progression-free survival (HR: 0.727; 95% confidence interval [CI]: 0.565, 0.935) | Source → |
| New Study Compares Treatments for Advanced Prostate Cancer | Prostate Cancer | meta-analysis | Talazoparib in combination with enzalutamide achieved a hazard ratio of 0.20 for radiographic progression-free survival. | Source → |
| Talazoparib Resistance Linked to Cancer Cell Transporters | Ovarian Cancer | lab-study | — | Source → |
| Real-World Study of Talazoparib in Advanced Breast Cancer | Breast Cancer | observational | The overall response rate was 63.1%. | Source → |
| Talazoparib's Effect on Cancer Drug Resistance | Lung Cancer | lab-study | — | Source → |
| Talazoparib Response Linked to BRCA Gene Mutation | Breast Cancer | lab-study | — | Source → |
| Talazoparib Improves Quality of Life and Pain in Men with Advanced Prostate Cancer | Prostate Cancer | phase-2 | Improvements in the estimated overall change from baseline (95% CI) in the mean worst pain were observed in all patients (-1.08 [-1.52, -0.65]) and the BRCA1/2 subset (-1.15 [-1.67, -0.62]). | Source → |
| New Study Tests Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.